These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

492 related items for PubMed ID: 16585503

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Daclizumab Therapy for Multiple Sclerosis.
    Bielekova B.
    Cold Spring Harb Perspect Med; 2019 May 01; 9(5):. PubMed ID: 29661806
    [Abstract] [Full Text] [Related]

  • 5. Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis.
    Sheridan JP, Zhang Y, Riester K, Tang MT, Efros L, Shi J, Harris J, Vexler V, Elkins JS.
    Mult Scler; 2011 Dec 01; 17(12):1441-8. PubMed ID: 21807759
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis.
    Perry JS, Han S, Xu Q, Herman ML, Kennedy LB, Csako G, Bielekova B.
    Sci Transl Med; 2012 Aug 01; 4(145):145ra106. PubMed ID: 22855463
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis.
    Zhang Y, McClellan M, Efros L, Shi D, Bielekova B, Tang MT, Vexler V, Sheridan JP.
    Mult Scler; 2014 Feb 01; 20(2):156-64. PubMed ID: 23846354
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation.
    Hao J, Campagnolo D, Liu R, Piao W, Shi S, Hu B, Xiang R, Zhou Q, Vollmer T, Van Kaer L, La Cava A, Shi FD.
    Ann Neurol; 2011 Apr 01; 69(4):721-34. PubMed ID: 21425186
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Dysregulation of regulatory CD56(bright) NK cells/T cells interactions in multiple sclerosis.
    Laroni A, Armentani E, Kerlero de Rosbo N, Ivaldi F, Marcenaro E, Sivori S, Gandhi R, Weiner HL, Moretta A, Mancardi GL, Uccelli A.
    J Autoimmun; 2016 Aug 01; 72():8-18. PubMed ID: 27157273
    [Abstract] [Full Text] [Related]

  • 16. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.
    Bielekova B, Howard T, Packer AN, Richert N, Blevins G, Ohayon J, Waldmann TA, McFarland HF, Martin R.
    Arch Neurol; 2009 Apr 01; 66(4):483-9. PubMed ID: 19364933
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Daclizumab in multiple sclerosis.
    Perez-Miralles FC.
    Rev Neurol; 2018 Apr 16; 66(8):271-282. PubMed ID: 29645071
    [Abstract] [Full Text] [Related]

  • 19. Anticipated benefits and surprising effects of daclizumab in multiple sclerosis.
    Stüve O, Greenberg BM.
    Lancet Neurol; 2010 Apr 16; 9(4):337-8. PubMed ID: 20163991
    [No Abstract] [Full Text] [Related]

  • 20. Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation.
    Gross CC, Schulte-Mecklenbeck A, Rünzi A, Kuhlmann T, Posevitz-Fejfár A, Schwab N, Schneider-Hohendorf T, Herich S, Held K, Konjević M, Hartwig M, Dornmair K, Hohlfeld R, Ziemssen T, Klotz L, Meuth SG, Wiendl H.
    Proc Natl Acad Sci U S A; 2016 May 24; 113(21):E2973-82. PubMed ID: 27162345
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.